Cagrilintide Research Guide: Long-Acting Amylin Analog & Satiety
Cagrilintide is a long-acting amylin analog studied alongside GLP-1 S (CagriSema) for additive effects on satiety, gastric emptying, and weight research.
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analog of amylin — the 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. A fatty-acid chain attached to the peptide backbone enables albumin binding and extends its circulating half-life.
Mechanism of action
Amylin acts on heterodimeric amylin receptors — the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs). Central activation in the area postrema and hindbrain slows gastric emptying, suppresses postprandial glucagon, and promotes satiety.
Cagrilintide replicates this profile with extended duration. In Phase-2 trials, monotherapy produced ~6–10% body-weight reduction over 26 weeks; the CagriSema combination has shown additive effects beyond GLP-1 S alone.
Half-life
Published pharmacokinetic data place the plasma half-life at approximately 7 days.
Compliance reminder
Cagrilintide is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is Cagrilintide?
Cagrilintide is a long-acting, acylated analog of amylin — the pancreatic peptide co-secreted with insulin from beta cells. Its extended half-life is the basis for the weekly interval used in the published trial literature.
Mechanism?
Amylin binds to amylin receptors (calcitonin receptor + RAMP heterodimers) in the brain and periphery to slow gastric emptying, suppress glucagon secretion, and promote satiety. Cagrilintide replicates these effects with extended duration.